GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2015Título de revista
EUROPEAN JOURNAL OF CANCER
Tipo de contenido
Artigo
![](/xmlui/themes/Mirage2//images/final_lines.png)